Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC

Najib Ben Khaled, Raphael Mohr, Leonie S. Jochheim, Valentina Zarka, Monika Karin, Fabian Artusa, Julia M. Schütte, Vera Himmelsbach, Ursula Ehmer, Katrin Böttcher, Friedrich Foerster, Simon Johannes Gairing, Paula Bark, Alexander Weich, Ignazio Piseddu, Monika Rau, Bernhard Scheiner, Lorenz Balcar, Marino Venerito, Philipp Heumann, Arne Kandulski, Catherine Leyh, Christoph Roderburg, Tom Lüdde, Matthias Pinter, Julia Mayerle, Jens U. Marquardt, Fabian Finkelmeier, Enrico N. De Toni, Andreas Geier, Florian P. Reiter

Open source

DOI: 10.1016/j.jhepr.2026.101818
Published: 2026-06
Container: JHEP Reports
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jhepr.2026.101818,
  title = {Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC},
  author = {Najib Ben Khaled and Raphael Mohr and Leonie S. Jochheim and Valentina Zarka and Monika Karin and Fabian Artusa and Julia M. Schütte and Vera Himmelsbach and Ursula Ehmer and Katrin Böttcher and Friedrich Foerster and Simon Johannes Gairing and Paula Bark and Alexander Weich and Ignazio Piseddu and Monika Rau and Bernhard Scheiner and Lorenz Balcar and Marino Venerito and Philipp Heumann and Arne Kandulski and Catherine Leyh and Christoph Roderburg and Tom Lüdde and Matthias Pinter and Julia Mayerle and Jens U. Marquardt and Fabian Finkelmeier and Enrico N. De Toni and Andreas Geier and Florian P. Reiter},
  year = {2026},
  journal = {JHEP Reports},
  doi = {10.1016/j.jhepr.2026.101818},
  url = {https://doi.org/10.1016/j.jhepr.2026.101818}
}

RIS

TY  - JOUR
TI  - Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC
AU  - Najib Ben Khaled
AU  - Raphael Mohr
AU  - Leonie S. Jochheim
AU  - Valentina Zarka
AU  - Monika Karin
AU  - Fabian Artusa
AU  - Julia M. Schütte
AU  - Vera Himmelsbach
AU  - Ursula Ehmer
AU  - Katrin Böttcher
AU  - Friedrich Foerster
AU  - Simon Johannes Gairing
AU  - Paula Bark
AU  - Alexander Weich
AU  - Ignazio Piseddu
AU  - Monika Rau
AU  - Bernhard Scheiner
AU  - Lorenz Balcar
AU  - Marino Venerito
AU  - Philipp Heumann
AU  - Arne Kandulski
AU  - Catherine Leyh
AU  - Christoph Roderburg
AU  - Tom Lüdde
AU  - Matthias Pinter
AU  - Julia Mayerle
AU  - Jens U. Marquardt
AU  - Fabian Finkelmeier
AU  - Enrico N. De Toni
AU  - Andreas Geier
AU  - Florian P. Reiter
PY  - 2026
JO  - JHEP Reports
DO  - 10.1016/j.jhepr.2026.101818
UR  - https://doi.org/10.1016/j.jhepr.2026.101818
ER  -

APA

Khaled, N. B., Mohr, R., Jochheim, L. S., Zarka, V., Karin, M., Artusa, F., Schütte, J. M., Himmelsbach, V., Ehmer, U., Böttcher, K., Foerster, F., Gairing, S. J., Bark, P., Weich, A., Piseddu, I., Rau, M., Scheiner, B., Balcar, L., Venerito, M., Heumann, P., Kandulski, A., Leyh, C., Roderburg, C., Lüdde, T., Pinter, M., Mayerle, J., Marquardt, J. U., Finkelmeier, F., Toni, E. N. D., Geier, A., & Reiter, F. P. (2026). Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC. JHEP Reports. https://doi.org/10.1016/j.jhepr.2026.101818

Source records

crossref · retrieved 2026-09-27T04:02:46.483Z